Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) has shared an announcement.
Ascletis Pharma Inc. has announced the dosing of the first participants in its U.S. Phase IIa study of ASC30, a once-monthly subcutaneous depot formulation of a small molecule GLP-1 receptor agonist, for the treatment of obesity. The study aims to evaluate the safety, tolerability, and efficacy of ASC30, which has demonstrated a 36-day half-life, supporting its monthly administration. This development positions Ascletis as a competitive player in the obesity treatment market, with ASC30 being the only once-a-month incretin with a half-life greater than the intended dosing interval, potentially offering better tolerability compared to existing treatments.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is known for its proprietary Ultra-Long-Acting Platform (ULAP) which has been used to develop small molecule compounds for obesity treatment.
Average Trading Volume: 5,586,127
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.39B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.